UPDATE : Monday, March 30, 2020
Celltrion launches third biosimilar in EU
  • By Lee Han-soo
  • Published 2018.05.04 17:21
  • Updated 2018.05.04 18:16
  • comments 0

Celltrion Healthcare said Thursday that it has started marketing Herzuma (Original: Herceptin), an anticancer antibody biosimilar, in the U.K.

Herzuma is an anti-cancer antibody biosimilar used for the treatment of breast and stomach cancer. Celltrion received approval from the Ministry of Food and Drug Safety in 2014.

The product launch comes after the company received sales approval from the European Medicines Agency (EMA) in February, Herzuma is the third biosimilar product the company has launched in Europe, followed by Remsima, an autoimmune disease treatment, and Truxima, a blood cancer treatment.

According to Celltrion, Remsima has steadily increased its market share in the European rheumatoid arthritis drug market and has surpassed the market share of the original in the fourth quarter of last year. Also, Truxima has recorded a market share of 58 percent in the Netherlands and 43 percent in the U.K. within a year of its launch.

Celltrion expects that its biosimilars will continue to grow its market shares in the EU as the drugs are gaining more and more reputation from the European medical community. The company also forecasts that such aspects will allow Herzuma to settle into the European market quickly.

Starting with the launch in U.K., the company plans to expand its sales reach to other major countries in Europe, including Germany, Netherlands, Portugal, Spain and Ireland this year.

“Celltrion's reputation is becoming more robust as it has increased its share of the market after the launch of Remsima and Truxima in Europe,” a company official said. “The newly introduced Herzuma will also lead the European market with its strengths such as rapid infusion, abundant clinical data and improved convenience.”


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top